|
miRNAs | Cancer type | Decrease/increase | Type of histone modification | Reference |
|
miR-127 | Primary human tumors | Decrease | Increased histone H3 acetylation and H3-K4 methylation | [37] |
miRNA-1260b | Prostate cancer cells | Increase | Increased H3K9-me2, H3K9me3 and H3K27me3 | [38] |
miR-124a | Acute lymphoblastic leukemia | Decrease | Decreased levels of 3mk4H3 and AcH3 and increased levels of 2mK9H3, 3mK9H3, and 3mK27H3 | [39] |
let-7e, miR-1246, miR-1826, and miR-361-5p | Breast cancer | Decrease | Decreased H3K4me3 | [40] |
miR-615 | Prostate cancer | Increase | Increased H3K9 acetylation | [41] |
miR-29 | B-cell lymphomas | Decrease | Increased histone deacetylation and trimethylation | [42] |
miR-15a, miR-16, and miR-29b | Chronic lymphocytic leukemia | Decrease | Increased histone deacetylation | [36] |
miR-15a and miR-16 | Non-Hodgkin B-cell lymphomas | Decrease | Increased histone deacetylation (HDAC3) | [43] |
miR-31 | Breast cancer | Decrease | Increased methylation | [44] |
miR-31 | Adult T-cell leukemia | Decrease | Increased H3K9 and H3K27 methylation | [45] |
miR-23a | Human leukemic Jurkat cells | Decrease | Increased deacetylation (HDAC4) | [46] |
miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b | Hepatocellular carcinoma | Decrease | Increased histone H3 lysine 27 (H3K27) trimethylating (EZH2) | [47] |
miR-449 | Hepatocellular carcinoma | Decrease | Increased histone deacetylation (HDAC1–3) | [48] |
miR-224 | Hepatocellular carcinoma | Increase | Increased histone acetyltation (Ep300) | [30] |
miR-155 | Breast cancer | Increase | Decreased H2A and H3 deacetylation (HDAC) | [31] |
|